Christopher & Dana Reeve Foundation Research Vision

Catalyze, Energize, and Educate

Vision

Curing spinal cord injury and improving quality of life for individuals and families impacted by paralysis

No FDA approved treatment for any SCI associated outcome



Pathophysiology of SCI

Acute (<48hours)

Spinal cord compression/transection

Neurons and oligodendrocytes damaged

Blood-spinal cord barrier compromised

Influx of inflammatory cells

Spinal cord swelling

Sub-Acute (48h to 14 days)

Ischemia and excitotoxity

NMDA, AMPA, Kainate receptor activation

Reactive Oxygen Species

Intermediate (14 D to 6 months)

Cystic cavitations coalesce to form barrier

Loss of tissue volume containing extracellular fluid, thin bands of connective tissue and macrophages

Chronic (>6 months)

Glial scars formed of reactive astrocytes

Inflammatory cells cause secretion of proteins that are inhibitory to axonal growth (chondroitin sulfate proteoglycan)

Inhibitors of axon regeneration (e.g., Nogo)



How do we get to the long-term vision?

Robust Clinical Pipeline

CNS trials have only a 9% chance of achieving regulatory approval!

Currently <100 unique clinical trials in SCI*

#1: INCREASE CLINICAL TRIALS

- More clinical trials increase chances of success

#2: DIVERSE CLINICAL TRIALS

- Diverse devices, therapeutics, and drug targets

#3: SMART CLINICAL TRIALS

- Well-designed trials that will be informative even if they fail

* Excluding exercise and food supplements

Neuroplasticity Clinical Trials

Anti-RGMa (Elezanumab-ABT555 and MT-3291) Phase II Abbvie and Mitsubishi

NervGen291 Phase1b/2

Intermittent hypoxia Phase I/II U of Colorado and Spaulding Rehab

Nogo Trap (Axer-204) Phase 1/II ReNetX

Cell Replacement Clinical Trials

OP1 Oligodendrocyte Progenitor Cells

Mesenchymal Stem Cells Phase II Mayo Clinic

Neural Stem Cells Phase I Neuralstem

IPSCs Memorial Hermann

Schwann cells Phase I U of Miami

Neuro-Spinal Scaffold Phase I In Vivo Therapeutics



CHRISTOPHER & DANA REEVE FOUNDATION
TODAY'S CARE. TOMORROW'S CURE.®

Bioelectric Stimulation Clinical Trials

Transcutaneous Stimulation
Onward

Epidural Stimulation
Onward

Brain-Spinal Interface
NeuroRestore and Onward

Reeve SAB

Jim Guest MD, PhD

Ona Bloom, PhD

Chet Moritz PhD

Joanna Stanicka PhD

Cristin Welle, PhD

Armin Curt MD FRCPC

Rex Marco MD

CHRISTOPHER & DANA REEVE FOUNDATION
TODAY'S CARE. TOMORROW'S CURE.®

Reeve Foundation Research Vision

Establish Foundation as the main catalyst for field enabling research

Catalyze

Proof-of-concept clinical trials

- -Bladder
- -BSI

Energize

Reeve SCI Investor Symposium with Lineage Cell Therapeutics

Educate

Open Data and Research Tools

Catalyze

Bladder

Brain Spine Interface



Energize

Annual SCI Investor Symposium

Reeve and Spinal Research Pre-Clinical RFA 2024

CHRISTOPHER & DANA REEVE FOUNDATION
TODAY'S CARE. TOMORROW'S CURE.®

Educate

Open Data

Research Services

PsychoGenics
Transforming CNS Discovery